The authors conducted a prospective trial to assess the feasibility of real time central molecular assessment of kidney transplant biopsy samples from 10 North American or European centers. Biopsy samples taken 1 day to 34 years posttransplantation were stabilized in RNAlater, sent via courier overnight at ambient temperature to the central laboratory, and processed (29 h workflow) using microarrays to assess T cell-and antibody-mediated rejection (TCMR and ABMR, respectively). Of 538 biopsy samples submitted, 519 (96%) were sufficient for microarray analysis (average length, 3 mm). Automated reports were generated without knowledge of histology and HLA antibody, with diagnoses assigned based on Molecular Microscope Diagnostic System (MMDx) classifier algorithms and signed out by one observer. Agreement between MMDx and histology (balanced accuracy) was 77% for TCMR, 77% for ABMR, and 76% for no rejection. A classification tree derived to provide automated sign-outs predicted the observer sign-outs with >90% accuracy. In 451 biopsy samples where feedback was obtained, clinicians indicated that MMDx more frequently agreed with clinical judgment (87%) than did histology (80%) (p = 0.0042). In 81% of feedback forms, clinicians reported that MMDx increased confidence in management compared with conventional assessment alone. The authors conclude that real time central molecular assessment is feasible and offers a useful new dimension in biopsy interpretation. ClinicalTrials.gov NCT#01299168.
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Introduction
Histologic assessment of biopsy samples has played a major role in the evolution of transplantation but has inherent limitations. Histologic lesions are relatively non-specific and require consensus guidelines to specify when the lesions permit a diagnosis to be assigned. The creation of such guidelines is necessarily empirical because there is no external standard for validation (1) . Histology requires subjective judgment by pathologists that has limited reproducibility between observers: j values for individual lesions are approximately 0.2-0.3 (where perfection is 1.0 and random is 0) and are not improved with training (2, 3) . Agreement between two observers is good when distinguishing normal from abnormal but not as good regarding specific diagnoses in abnormal biopsy samples (4) . For example, in kidney transplant biopsy samples where one pathologist diagnoses T cell-mediated rejection (TCMR), another pathologist will agree in approximately 50% of biopsy samples (5) . Agreement is less frequent in biopsy samples from heart (28%) (4) and lung transplants (18%) (6) . Consensus guidelines often incorporate questionable rules [e.g. diagnosing TCMR based on v-lesions alone (7, 8) ], requiring C4d staining in antibody-mediated rejection (ABMR) (9) (10) (11) , and the concept of "chronic allograft nephropathy" (12, 13) . Assessment of circulating donorspecific anti-HLA antibodies (DSAs) through the use of solid-phase assay with single antigen beads has provided important insights (14, 15) , but such assays have limitations (16) (17) (18) (19) (20) and complement-fixing DSAs must now be considered (20) .
In response to the limitations of conventional assessment, many areas of medicine are exploring molecular technologies in the quest for greater precision. We developed the Molecular Microscope Diagnostic System (MMDx) that assesses TCMR and ABMR in a reference set of biopsy samples using machine learning-derived classifier algorithms (21, 22) . This approach must be centralized because if microarrays are processed in multiple laboratories, variation in measurements between laboratories could make the classifiers unreliable.
The present prospective INTERCOMEX study, an extension of the International Collaborative Microarray Study (INTERCOM) trial (ClinicalTrials.gov NCT01299168), was performed to explore the feasibility of real time central diagnoses and to determine the relationship between such readings and local assessment in experienced centers. Biopsy samples in each center were immediately stabilized in RNAlater (Qiagen, Mississauga, Canada) and sent overnight by courier to be processed (RNA extraction and labeling, microarray assessment, and normalization of the measurements with the reference set biopsy samples) and analyzed by using predefined algorithms (22) . We processed 519 new biopsy samples in a 29 h biopsy processing workflow (excluding time in shipment) and compared the results both with local standard-of-care conventional assessment and with previous MMDx results. Although reports were all labeled "for research purposes only," clinicians were asked to compare the MMDx diagnoses with local histology assessment. All of the molecular measurements were interpreted as a probability of ABMR or TCMR by one observer (P.F.H.), and a decision tree was devised that incorporated all molecular measurements to reach conclusions to simulate the interpretation of the observer and reduce dependency on expert opinion. Note that MMDx reports also assess injury, atrophy/ fibrosis, and prognosis, but these are not included in the present analysis of rejection.
Materials and Methods
Histology classification and HLA antibody assessment INTERCOMEX was a prospective study that aimed to assess the feasibility of real time MMDx biopsy assessment by using microarrays and to compare central MMDx assessment with local standard-of-care in experienced centers. All biopsy samples were taken with informed consent in protocols approved by the local institutional review board in each center. Biopsy samples taken between September 2014 and October 2015 were assessed locally by histology according to the standard-of-care in each center, with all centers nominally following Banff 2013 guidelines (11) . As expected, local standard-of-care methods for assessing HLA antibody and histology varied, including ELISA, complement dependent cytotoxicity-anti-human globulin panels, FlowPRA (One Lambda Canoga Park, CA, USA) screen, or Luminex (One Lambda Canoga Park, CA, USA) single antigen bead testing, interpreted by local practice. The C4d staining methods (immunofluorescence or immunoperoxidase) and grading were previously described (23, 24) .
Microarray assessment
One 16-or 18-gauge biopsy core or portion of a core was placed immediately in RNAlater, stored overnight at 4°C, shipped via courier at room temperature, and, if not processed immediately, stored at À20°C. RNA was extracted by the TRIzol-chloroform method (Invitrogen, Cergy Pontoise, France) and purified on QIAGEN (Qiagen, Hilden, Germany) columns, and 0.5 lg of total RNA was used for labeling. Biopsy samples from which sufficient RNA was isolated were processed with a modified procedure (total processing time 29 h). The first-strand DNA synthesis was carried out for 30 min, and second-strand synthesis was carried out for 1 h. The labeling (3 0 IVT Plus Kit; Affymetrix, Santa Clara, CA) was completed in 2 h, and labeled and fragmented cRNA was hybridized to the PrimeView GeneChip arrays (Affymetrix) according to the manufacturer's protocols. Microarrays were scanned by using GeneArrayScanner (Affymetrix) and processed with GeneChip Operating Software Version 1.4.0 (Affymetrix). When the RNA yield was too low for the modified procedure (<80 ng/mL), the standard labeling procedure was used (first-and second-strand DNA synthesis totaled 3 h 45 min and labeling was for 16 h). In such cases, the Ratio G correction method was used to minimize batch effects (25) . Detailed protocols for microarray processing are available in the Affymetrix Technical Manual (www.affymetrix.com). The output was a .CEL file of measurements of expression of all probe sets. Results of technical and biological replicates in the MMDx system are presented elsewhere (26) .
Assigning diagnoses and sign-out reports
Once a microarray processing produced a .CEL file, an R script was used to generate the report (Figure 1 ), which shows 26 scores generated by classifiers or transcript sets (e.g. acute kidney injury [AKI]) (pages 1 and 2). All classifiers and the meaning of their designations and abbreviations are explained in Table S1 . The three main published classifiers were the TCMR score (TCMRt) (5), the ABMR score (ABMRpm) (23) , and the rejection score (27) . TCMR and ABMR classifiers were established in a set of 403 biopsy samples (5, 23) and validated in a subsequent set of 300 biopsy samples in the INTERCOM study (24, 28) , creating a combined reference set of 703 biopsy samples (29) , here called "Population 703." New classifiers were derived from rejection diagnoses included TCMRt(bkx), Rejection(bk), ABMRpm(x), ABMRpmx, ABMRp, and ABMRp(mx), all minor variants on the published algorithms [e.g. including mixed (x) in the ABMR classifier (ABMRpmx)]. Additional classifiers were based on rejection-related histology lesions. A hyalinosis-based molecular classifier (histology ah-score) was included because ah-lesions are related to risk of nonadherence (30) . (Corrected for time posttransplantation, lack of ah-lesions and of associated molecular changes in the biopsy predicts a higher probability of rejection in the biopsy, and a molecular classifier can detect this risk: if the ah-lesion classifier score is low, the probability of rejection is higher and the probability that nonadherence has triggered that rejection is increased [unpublished data].) Everything else; and ci >1= probability of ci >1), and the summarized transcript scores for parenchymal transcripts (KT1) (31, 32) and AKI (AKI transcripts or injury-repair response associated transcripts) (33) . The location of the new biopsy sample is summarized on page 3 of the report in terms of the histologic diagnoses, molecular measurements, and 1-and 3-year graft survival (postbiopsy) of its 50 nearest reference set neighbors.
Nearest-neighbors analysis

Classification tree
All reports were signed out by one observer (P.F.H.), taking into consideration all classifiers in the MMDx report. As a model for how the classifiers could be interpreted mathematically to simulate the sign-out by an expert observer, a classification tree was built using all of the reports and their sign-outs. The rpart and rpart.plot packages in "R" were used to construct the classification tree shown in Figure 2 (34), based on published methods (35, 36) .
Results
Patient and biopsy populations
The population included 519 biopsy samples from 491 patients from 10 centers ( Table 1 ). The distribution of biopsy diagnoses by center is shown in Table S2 . The recipients had a mean age of 51 years at biopsy; 294 (60%) were male, and most kidneys were from deceased donors (n = 376, 78%). Biopsy samples were a median of 1423 days posttransplantation (1 day to 12 371 days [34 years]). The main indications for biopsy were dysfunction, investigation of proteinuria or DSAs, or follow-up from the previous biopsy. Protocol biopsy samples from standard-risk recipients were not included.
Histology diagnoses and HLA antibody assessment in INTERCOMEX compared with Population 703
The principal histologic diagnoses in 519 biopsy samples suitable for microarray assessment (Table 2) were ABMR (n = 88, 17%), ABMR suspected (n = 10, 2%), TCMR (n = 29, 6%), AKI (n = 43, 8%), "borderline" (n = 31, 6%), unexplained atrophy/fibrosis (n = 84, 16%), and "no major abnormalities" (n = 141, 27%). While the distribution of histology diagnoses (case mix) in INTERCOMEX was similar to that of the previous Population 703, ABMR was more frequent, and TCMR and borderline were less frequent. The diagnosis of "transplant glomerulopathy" was less often assigned in INTERCOMEX, perhaps because of the recent recognition that such cases are often better classified as ABMR (37) .
In HLA antibody assessment, 37% of INTERCOMEX patients were DSA positive at the time of biopsy, compared with 29% in Population 703 (Table 3) . DSA was positive at the time of transplantation for 133 biopsy samples, mostly (69%) from the Paris programs, which transplant high-risk DSA-positive recipients.
Biopsy size and RNA quantity, quality, and yield Of biopsy samples submitted to INTERCOMEX, 96% (519 of 538) could be processed, with average size of 3 mm, either 16 or 18 gauge, yielding high-quality RNA as indicated by the measurements in Table 4 . The 19 biopsy samples that could be not processed were too small or had degraded RNA due to biopsy handling errors at the local center (e.g. delay in placing the core in RNAlater).
Of 519 biopsy samples processed, 26 (5%) yielded too little RNA for 1-day processing and were processed with the Affymetrix 2-day method to increase the yield of labeled RNA (see Materials and Methods).
MMDx rejection classifier scores compared with histology diagnosis Table 5 shows the median MMDx rejection-related scores for three published classifier algorithms-TCMRt .) The median ABMRpm score was 0.52 in histologic ABMR and 0.56 in biopsy samples termed "mixed" but was generally below cutoff (<0.2) in other conditions. The median TCMRt score was elevated in many but not all histologic TCMR biopsy samples (0.33) and mixed biopsy samples (0.31). [As in previously reported, some biopsy samples diagnosed as TCMR through histology did not have molecular TCMR (38) ]. The median rejection score was elevated in histologic ABMR (0.53), TCMR (0.47), and mixed rejection (0.88) and in some BK biopsy samples, usually those that also had an elevated TCMR score.
Assessment of "positive" rejection classifier scores While molecular classifier scores are probabilistic, for comparison with histology we assigned arbitrary cutoff to permit designation as positive versus negative. Accuracy of rejection-related sign-out diagnoses for histology diagnoses While the MMDx report shows many classifiers and scores to estimate rejection and injury (22) (see Table S1 for the algorithms and nomenclature), the present analysis focuses only on the rejection-related classifiers. The MMDx rejection diagnoses were assigned by one observer (P.F.H.) based on all rejection-related classifiers plus time from posttransplantation to biopsy (TxBx) (although TxBx did not affect the molecular interpretation). Note that actual histologic diagnoses, lesions, and DSA status were never used for report sign-outs-only molecular classifiers based on these variables in the reference set.
The agreement between MMDx sign-out and histology is shown in Table 7 . The balanced accuracy (mean of the specificity plus sensitivity, which takes into account the imbalance in the size of the classes) of the molecular diagnosis versus histology diagnosis was 77% for the Other indications listed included nonadherence, BK infection, congenital renal hypoplasia, increase in donor-specific anti-HLA antibodies (DSAs), evaluate recurrent kidney disease, hematoma, nephrotic syndrome, swelling near kidney, rise in serum creatinine, and investigate hematuria. ABMR and TCMR and 76% for all rejection (balanced accuracy takes into account the imbalance in the size of the classes).
While observer P.F.H. signed out all reports for consistency, subsequent studies of the agreement of other trained observers with the P.F.H. sign-out showed >90% agreement (data not shown).
Building a classification tree for automated sign-outs by using all rejection-related classifiers We created a classification tree for predicting P.F.H. diagnoses, to make automated sign-out without expert interpretation and to examine which classifiers were most important for sign-out ( Figure 2 ). The tree generation algorithm was asked to predict the diagnoses of the P.F.H. sign-out, summarized as nonoverlapping categories: TCMR, ABMR, mixed, or no rejection. The program selected which molecular predictor variables to use, including all rejection-related molecular classifier scores derived from histologic diagnoses (ABMR, TCMR, or all rejection), lesions (cg, g, i, t, ptc, and ah lesions); or DSA status. TxBx was also included. These were the variables available to P.F.H. to sign out the reports.
The classification tree predicted P.F.H. diagnoses with accuracy of 91.1%. Note that only molecular variables are used: for example, the "g" in Figure 2 is the molecular classifier derived using glomerulitis (g) lesions, not the actual g lesions, which were unknown at diagnosis. The classification tree chose only the ABMRpm, ABMRpmx, TCMRt, and g-lesion classifiers.
Tree models have a tendency for overfitting. We dealt with this using the "prune.rpart" function with default settings. The observed accuracy using the full, unvalidated model with pruning (91.1%) was only slightly inflated compared with that obtained by pruning within 10-fold cross-validation loops (90.3%). Thus, this model or a variation thereof can be used to create an automated report sign-out using all of the classifiers plus TxBx.
Feedback from clinicians
The clinician investigators in each center provided clinical feedback for 508 (87%) of 519 biopsy samples (Table 8) .
Potential sources of bias in the feedback are discussed next.
The clinicians agreed with MMDx and histology in 367 (72%) biopsy samples. Clinicians agreed with MMDx but disagreed with histology in 76 (15%) samples. Clinicians agreed with histology but disagreed with MMDx in 9% Results as specified by the tissue typing laboratory at the center. 3 Of the 133 DSA-positive results at transplantation, 92 (69%) of tests were performed in Paris. Quality of labeled and hybridized cRNA (estimate of degradation). 4 Twenty-four samples had integrity number <6, but only three had actin and GAPDH ratios >3. All had the 260:280 ratio = 2. The decision to exclude a biopsy was made on the lack of sufficient labeled cRNA or on severe problems with RNA quality measurements. These abbreviations designate the algorithm used to generate the classifier, also see Figure 1 and Table S1 . 3 Positive means for rejection-related diagnoses (above the cutoff) are indicated in bold. 4 The medians were low because only 4 of 9 were positive. and disagreed with both in 4%. Overall, clinicians disagreed with histology (19%) more often than with MMDx (13%) (v 2 p = 0.0042, two sided). As interpreted by clinicians, there were disagreements between MMDx and histology results in 24% of biopsy samples (Table 8) , similar to our balanced accuracy calculations earlier.
In 82% of biopsy samples for which feedback was provided, investigators noted that MMDx would provide increased confidence for management decisions. Although MMDx reports were designated "for research purposes only," Table 8 shows many MMDx reports had the potential to affect clinical management.
Discussion
We assessed the feasibility and potential clinical impact of central molecular testing of kidney transplant biopsy samples for rejection in a prospective consented trial. We performed microarray assessment of biopsy samples shipped via courier at ambient temperature, usually processed starting the next business day after arrival. While the core or portion of core received was usually small (mean 3 mm), 96% of biopsy samples (519 of 538) were readable, and most of these could be processed in a modified 29 h work flow. RNA quality and yield were almost uniformly high, reflecting the reliability of biopsy acquisition and stabilization, even in inexperienced centers. MMDx performed in real time as well as it had during development and validation in Population 703 and strongly agreed with histology assessment, with some disparities, as expected (5, 23) . Feedback received for 451 biopsy samples indicates that clinicians agreed with MMDx more often than with their local biopsy assessment and indicated that MMDx would give them more confidence for clinical management. The report sign-out diagnosis of rejection agreed with histology with a balanced accuracy of 76-77%. A classification tree was built to provide automated prediction of P.F.H. sign-outs with 90% accuracy, indicating that objective sign-outs can be achieved. The results indicate the feasibility of 70%  84%  51%  92%  81%  77%  TCMR   3   62%  93%  45%  96%  90%  77%  Rejection  78%  74%  90%  54%  77%  76% ABMR, antibody-mediated rejection; INTERCOMEX, International Collaborative Microarray Study Extension; MMDx, Molecular Microscope Diagnostic System; NPV, negative predictive value; PPV, positive predictive value; TCMR, T cell-mediated rejection. 1 Using only the 504 (of 519) biopsy samples where histologic diagnoses were available. 2 The average of the sensitivity and specificity. 3 Mixed rejection was considered a positive call for both ABMR and TCMR in both MMDx and histology. Both totals are >504 because each diagnosis of "mixed" counts twice. Numbers for MMDx: ABMR (n = 100), TCMR (n = 42), NR (n = 374); total = 516. Numbers for histology: ABMR (n = 136), TCMR (n = 58), no rejection (n = 326); total = 520. Feedback was collected either verbally via teleconference, extrapolated from histology reports and clinical feedback, or through clinical research forms from the principal investigators at each site. These data were then entered into the scientific data management system, exported as a spreadsheet, and assigned to appropriate categories to obtain final percentages.
central real time molecular assessment and the potential to improve assessment and direct management of problematic kidney transplantations.
While the actual turnaround from biopsy to report was not recorded, the median time from biopsy to issuance of final report (excluding local biopsy samples) was 3 working days (72 h) in this study: one night for the courier, wait until the morning after arrival to begin processing, and 29 h processing. In an actual service environment, the median time would be 48 h because processing would start as soon as the courier arrived.
While clinician feedback on the MMDx reports was positive, such feedback could be potentially biased and we interpret it with circumspection. Feedback is subject to potential positive biases (e.g. novelty of the MMDx vs. histology) and negative biases (e.g. loyalty to local pathologists). Study of discrepancies based on clinical feedback is crucial to our ongoing strategies to refine both the MMDx and the histology classification, and a manuscript addressing such discrepancies is in preparation. In terms of the impact of MMDx on treatment decisions in discrepant biopsy samples, of 99 biopsy samples where MMDx and histology were considered discrepant, clinicians indicated that the MMDx report would influence treatment in 39 (39%) of samples.
While the numerous MMDx classifiers were interpreted by a knowledgeable observer for sign-out, the classification tree illustrates how a predictive model for automatically assigning diagnoses can be derived from these classifiers. A regression model could also have been used, but we preferred a tree-based model because of increased interpretability and because we believe it more accurately simulates the manner in which a human expert evaluates a collection of data such as that seen in the reports. As the MMDx evolves, the ultimate goal is automated probabilistic interpretations with minimal need for expert opinion.
The MMDx system is continuing to add improvements to enhance accuracy beyond the system available for sign-outs in the INTERCOMEX cohort reported here. A recent study of medulla content (unpublished data) (26) found that estimating percent medulla eliminates a potential source of error. Unlike histology, the MMDx system can read medulla, but biopsy samples that are all or mostly medulla should be flagged for adjusted interpretation of some classifiers and transcript set measurements. Medulla correction developed after the present INTERCOMEX study and will further improve MMDx (26) . The MMDx system also has the capacity to add new probe sets of interest such as transcripts from infectious agents. Finally, the issue of optimal biopsy size should be addressed. INTERCOMEX biopsy samples were relatively small at a mean of 3 mm because they were collected in a research protocol subject to institutional review board stipulations in each center. Future experience with larger cores will be of interest. Sample size is an issue for all biopsy samples of human organs, and the general rule "more is better" must be weighed against the increased risk of larger samples. Histology has strict rules for tissue adequacy to ensure sampling of arteries, glomeruli, and cortex, making some biopsy samples uninterpretable (e.g. pure medulla) and others questionable (e.g. too few glomeruli or arteries). MMDx can read smaller samples, but the impact of sample size on variability should be addressed as samples begin to be acquired outside the constraints of research protocols.
Central molecular interpretation offers an objective "second opinion" that adds to local histology findings to create a global understanding of each case and does not have to be assumed to be 100% correct to have value when faced with the uncertainty in histology diagnoses. Trial clinicians expressed 20% disagreement with local histology readings and MMDx showed 25% disagreement with histology, recalling the estimates of disagreement among pathologists and probably reflecting at least in part the inherent uncertainty in assessment of lesions. However, while we believe that the molecular assessments are more accurate than histology, the actual application of molecular measurements in kidney transplant biopsy samples will likely be as a new dimension added to histology and will have to be established in large-scale clinical experience.
Until now, histology guidelines had to be empirical because they lacked an external standard; they can now be assessed against MMDx assessments to compare potential improvements. Renal transplantation benefited from the Banff consensus guidelines (11) and will benefit from the improvements guided by comparison with the molecular dimension (38, 39) as endorsed by the Banff consensus (40) . Future histology revisions should aim not only for improved accuracy in disease assessment but also for improved agreement between observers. Histology uses arbitrary cutoffs to assign diagnoses, which we have noted could be replaced by probabilistic histology regression equations trained against the molecular phenotype (37) (38) (39) , although the practice of using histology lesion grades (0, 1, 2, or 3) rather than continuous numbers for lesion assessment is somewhat limiting. Many cases of histologic ABMR are probably false-positive, particularly early-stage ABMR before cglesions (37) . We have found that ptc-and g-lesions are nonspecific and can be produced by other diseases, including TCMR and AKI. It is also possible that ABMR can be missed on histology and detected by MMDx (e.g. in cases with ABMR but undetectable DSAs).
The evaluation of problematics transplantations with indications for biopsy must eventually use algorithms that combine molecular, histology, and HLA antibody assessment to ensure that each contributes where its capabilities are most useful. This will be particularly important as new treatments emerge for ABMR, not only to guide the initiation of therapy but also to monitor its effects. The algorithms will reflect consideration of prior probabilities, safety, value, and cost (unknown until commercialization). For example, in suspected rejection or investigation of de novo DSAs, MMDx could be prioritized, reducing the number of biopsy cores. In patients with a strong probability of recurrent disease, histology could be prioritized, with a 3-mm core segment stabilized in RNAlater for future processing if necessary.
Centralized MMDx assessment cannot be replaced by local molecular testing until the problems of variation between and within local molecular platforms are resolved, because diagnostic classifier equations are dependent on normalization of the new sample against the reference set. Thus, molecular tissue assessment in cancer that requires quantitation of mRNA is generally centralized. The well-known variation in local HLA antibody assessment illustrates the difficulty in creating standardizing molecular measurements with the kits and equipment used in many independent laboratories. We are also evaluating formalin-fixed paraffin-embedded tissue for molecular assessment, but our initial results in 70 biopsy samples indicate that low RNA yield and damage to the RNA make formalin fixation a distinctly inferior choice compared with RNAlater-stabilized biopsy samples (unpublished results). Moreover, simple measurement of rejection-associated genes is less accurate than the multiple classifier approach used here and can be misleading because the rejection genes can be increased in other injuries and diseases (41) .
Comparing INTERCOMEX with the earlier Population 703 reveals trends in the prevalent renal transplant population, including a higher percentage of anti-HLA DSAs and ABMR and less TCMR. Perhaps the growing use of maintenance immunosuppression based on the Symphony study (42) is decreasing TCMR but making TCMR triggered by nonadherence (43) (44) (45) and TCMR-like changes in the context of polyomavirus (46) relatively more prominent. Such changes in phenotype over time must be monitored in diagnostic systems because they influence the accuracy of guidelines and algorithms. The centralized MMDx system offers to maintain opportunity for an ongoing reference population for this purpose.
The present analysis found that the "borderline" category-the presence of TCMR-like i-and t-lesions below the threshold required for diagnosis of TCMR-is usually not rejection, consistent with previous analyses (29) . TCMR-like i-and t-lesions are common in AKI, in inflammatory primary renal diseases such as glomerulonephritis (47, 48) , and even in ABMR (29) and are truly nonspecific-the response to kidney wounding. Thus, arbitrary i-score and t-score cutoffs used for borderline and for TCMR can be met in the absence of TCMR, and it is not surprising that histologic borderline is actually only a reflection of molecular TCMR in 25% of cases, and histologic TCMR is only actually molecular TCMR in 60% of cases (29) . The fact that accurate molecular estimates require only 3 mm of tissue indicates that molecular changes are more uniform than histology changes, as shown in biological replicate studies (26) , bypassing some concerns about sampling error and patchiness of T cell infiltrates. This illustrates how the complete understanding of a case can benefit from adding the molecular dimension.
In molecular diagnostics, one of the big challenges is to establish "clinical value" (i.e. the incremental gain provided by a new test). MMDx assessments are superior to conventional assessments for predicting outcomes (23, 49) . The suggestion that a molecular test be required to change hard outcomes such as survival differences in a controlled trial is a challenge that has in effect never been achieved by any test in transplant history. For example, the Banff system during 26 years has made many diagnostic advances but none of them have been validated with hard outcomes in controlled trials. Similarly, the introduction of Luminex testing for HLA antibody assessment changed practice because it was technically superior, but it never met the criterion of changing hard outcomes. How MMDx is used in a particular center may vary, depending on concerns about local standard-of-care. Theoretically, MMDx could replace histology, be used in parallel with histology, or be used to resolve problems. Nevertheless, in the clinic where decisions must be made, the fact that the clinicians indicated that MMDx would add valuable support for clinical decisions beyond their current standard-ofcare is encouraging for further development of MMDx testing.
